Treatment related toxicities with combination braf and mek inhibitor therapy in resected stage iii melanoma

HIGHLIGHTS

• who: Morgan Homan from the University of Texas MD Anderson Center, United States have published the article: Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma, in the Journal: (JOURNAL)
• what: Recurrent pyrexia and chills occurred in 17 patients (85%) and was the primary reason for treatment discontinuation in nine patients (45%). The authors report the findings of the side effects of adjuvant combination BRAF and MEK inhibition to demonstrate the frequency and severity of toxicities.
• future: Studies with larger numbers of patients are needed to validate . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.